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Abstract
Three networks/projects involving 27 European countries were established to investigate the quality of second-line drug
(SLD) susceptibility testing with conventional and molecular methods. 1. The ‘‘Baltic-Nordic TB-Laboratory Network’’
comprised 11 reference laboratories in the Baltic-Nordic States. They performed SLD testing in the first phase with a panel of
20 Mycobacterium tuberculosis strains. After several laboratories made technical changes a second panel of 10 strains with a
higher proportion of resistant strains were tested. Although the concordance for Ofloxacin, Kanamycin, and Capreomycin
was consistently high, the largest improvements in performance were achieved for the analysis of Ofloxacin resistant (from
88.9 to 95.0%), and Capreomycin resistant (from 71.0 to 88.9%) strains. 2. Within the FP7 TB PAN-NET project (EU Grant
agreement 223681) a quality control panel to standardize the EQA (External Quality Assurance) for first-line drugs (FLD) and
SLD testing for phenotypic and molecular methods was established. The strains were characterized by their robustness,
unambiguous results when tested, and low proportion of secondary drug resistances. 3. The (European Reference
Laboratory Network-TB) ERLN-TB network analyzed four different panels for drug resistance testing using phenotypic and
molecular methods; in two rounds in 2010 the 31 participating laboratories began with 5 strains, followed by 10 strains and
6 additional crude DNA extracts in 2011 and 2012 were examined by conventional DST and molecular methods. Overall, we
demonstrated the importance of developing inter-laboratory networks to establish quality assurance and improvement of
SLD testing of M. tuberculosis.
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Introduction
The accurate determination of drug susceptibility is crucial for
optimizing the treatment of tuberculosis (TB) and preventing
transmission of drug resistant M. tuberculosis strains. However, there
are methodological problems with current drug susceptibility
testing (DST) of M. tuberculosis. Worldwide, no standardized DST
methods for all SLDs exist. Laboratories perform tests using
various methods, all based on the observation of inhibition of
growth in media containing anti-tuberculosis drugs. In many
countries the proportion methods on egg- or agar-based media are
widely established, although the long turnaround time for
obtaining results is a known disadvantage of these techniques.
The DST methodologies for first-line drugs on solid media are
mostly standardized and accepted [1,2]. In order to improve turn-
around times numerous new techniques have been introduced.
Growth detection based on the measurement of CO2 production
(BACTEC 460TB, Becton Dickinson Microbiology Systems,
Sparks, MD [BD] and the MB/BacT system, bioMe´rieux, Marcy
l’Etoile, France) or oxygen consumption (mycobacterial growth
indicator tube system, BACTEC MGIT 960, [BD]) have been
developed. Although a variety of methods exist, the majority have
been replaced by the MGIT 960 method, since it is more versatile,
nonradiometric, and automated. The method has been widely
validated for the reliable and rapid testing of first-line (and some
second-line) drug susceptibilities of M.tuberculosis isolates [3–6].
The emergence of drug-resistant strains led to the increased
introduction of SLDs for tuberculosis treatment and subsequently
to the need to extend current methods to SLD susceptibility testing
[7]. Whereas the critical concentrations for SLD with BACTEC
460 were assessed more than ten years ago [8], comparable studies
were accomplished for MGIT more recently [9,10]. In 2008,
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during an WHO Expert Committee meeting in Geneva, critical
concentrations were specified in interim guidelines, which are
recommended to use for SLD [2].
The WHO/IUATLD Supranational Reference Laboratory
(SRL) network was created in 1994, to validate the accuracy of
the DST methods used in laboratories across the world and
support global drug resistance surveillance. Up until 2011, 28
WHO Supranational Reference Laboratories (SRLs) had actively
participated in 18 rounds of proficiency testing including FLD,
and since 2007 (14th round) also SLD demonstrating the success of
the network in producing a substantial improvement in perfor-
mance [11].
Although a functioning supranational network for DST exists,
proficiency testing especially for SLD was for a long time neglected
in both high and low income countries. In recent years, three
networks/projects were initiated to establish SLD testing with
conventional and molecular methods: the ‘‘Baltic-Nordic TB-
Laboratory Network’’ [12], the network in the WP3 of the TB
PAN-NET project (EU Grant agreement 223681), and the ECDC
(European Centre for Disease Prevention and Control) ERLN-TB network,
which was founded to generate a European proficiency testing
system for all mycobacterial diagnostic procedures. By summariz-
ing results and experiences from all three networks we aimed to
give an overview of current External Quality Assurance (EQA) of
SLD and the reliability of SLD results in reference laboratories in
the European region.
Materials and Methods
Study Design ‘‘Baltic-Nordic TB-Laboratory Network’’
Overall 11 laboratories participated in the study; all were
members of the ‘‘Baltic-Nordic TB-Laboratory Network’’, which
was created in 2001, primarily to ensure safe working conditions
for DST. The study was carried out in two phases: Phase I. This
phase was designed to compare the SLD susceptibility testing
results with a panel of 20 strains chosen by the NRC in Borstel,
Germany. All laboratories were free in their choice of which drugs
they wanted to test and DST methods used. In order to minimize
the risk of handling extensively resistant strains, the majority of
strains were drug susceptible with only a few exhibiting resistance.
Results were reported to Borstel, analyzed and discussed with all
participants. Phase II. In the second phase a set of 10 strains was
chosen and sent to the participants. The second panel comprised
proportionally more resistant strains than the first panel. In this
phase laboratories were allowed to test the strain repeatedly before
reporting the results. SLD testing results were again analyzed and
compared to results in phase I. A detailed questionnaire was sent
out requesting details of the respective methods that were
performed in the laboratories.
Participating Laboratories, Test Methods and Method of
Analysis
In each round 10 laboratories participated (9 were the same in
both rounds). The laboratories tested a maximum of 7 drugs,
(Amikacin, Capreomycin, Cycloserine, Ethionamide/Protiona-
mide, Kanamycin, Ofloxacin, PAS). The following methods were
applied: the proportion method on Lo¨wenstein-Jensen medium,
and the critical concentration method on 7H10 medium,
BACTEC 460 and MGIT 960 [13–15] media.
For the assessment of SLD susceptibility testing, results from all
laboratories and drugs used were included in the analysis. None of
the laboratories were chosen as an arbiter that defines the ‘‘true’’
result of resistance. A strain was defined as ‘‘susceptible or
‘‘resistant’’, based on the majority decision of laboratories, when
reporting the result of the strain. In the case of an equal score, the
respective strains were reanalyzed in Borstel by two alternative
methods and this result was applied. In a second step, the
concordance between results was estimated by the percentage of
laboratories having obtained this result.
Study Design ‘‘Work Package 3 of the TB PAN-NET’’
Overall 14 partner laboratories participated. Laboratories were
free to choose which methods to apply on any of the sent EQA
panels. In the first round a panel of 20 susceptible and resistant
strains were sent for FLD and SLD testing together with a
questionnaire to complete with the respective methods that were
performed in the laboratories. In an intermediate analysis some
laboratories investigated MIC levels of strains with doubtful
results. In the second round of panel testing 20 laboratory
generated strains were used for FLD and SLD conventional DST.
Some groups additionally performed molecular-based methods.
The results of both rounds were used to create a selection of
robustly characterized strains.
Study Design ‘‘ECDC ERLN-TB Network’’
Overall 31 laboratories participated in the study; all ensured
safe working conditions and were free to participate in any of the
sent EQA panels. The study was carried out in four phases. Until
now, four different rounds of quality control were accomplished.
Round 1 in spring 2010 included 5 strains for FLD DST. In
autumn 2010, SLD testing with phenotypic and molecular
methods were added. In autumn 2011 and 2012 a further 10
strains and 6 crude DNA extracts for FLD and SLD testing with
phenotypic and molecular methods were added.
All participants received an individual analysis of their
performance and a certificate summarizing the score obtained.
Results
‘‘Baltic-Nordic TB-Laboratory Network’’: Phase I
20 strains were analyzed by 10 laboratories. All reported results
were included except ‘‘borderline’’ and ‘‘no growth’’. The level of
concordance between the results was calculated (Table 1, upper
part, Phase I) and was higher between strains that were assessed
‘‘susceptible’’ compared to those that were assessed ‘‘resistant’’.
The highest levels of concordance were found for Kanamycin and
Ofloxacin with 98.3% and 98.9%, respectively. The lowest level of
concordance was found for Ethionamide at 82.9% and PAS at
92.0%, respectively. In order to improve the quality of SLD
various technical changes were implemented by members of the
network: (Table 2) Amikacin: One laboratory changed the
critical concentration from 4 to 1 mg/ml, two others from 2 to
1 mg/ml and used BACTEC MGIT 960 instead of BACTEC 460.
Capreomycin: Some laboratories switched from Capreomycin
to Capreomycin sulphate and changed the drug concentration
from 5 to 1.25 mg/ml in BACTEC 460 and from 1.25 to 2.5 mg/
ml now using the BACTEC MGIT 960 instead of the BACTEC
460 system. Instead of tap water deionised water was used as
diluent of the drug in one laboratory. Cycloserine: Although the
substance used was obtained from different companies, all used D-
cycloserine. All laboratories, except one which used Middlebrook
7H10 media had a slightly higher concentration of Cycloserine
(40 mg/ml) as critical concentration and revealed a lower number
of resistant strains than those, who used the lower 30 mg/ml
concentration. Nevertheless, the concentrations of D-Cycloserine
were retained. Ethionamide/Protionamide: One laboratory
switched from methanol to ethylene glycol, another from ethylene
glycol to DMSO as the solvent, and two switched from the
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BACTEC 460 to BACTEC MGIT 960 method. Another
laboratory reduced the drug concentrations tested from 2, 4,
and 6 to only the recommended critical concentration (Ethion-
amide 5 mg/ml; Protionamide 2.5 mg/ml). Kanamycin: Kana-
mycin is delivered as mono-sulphate or di-sulphate, but most used
the mono-sulphate. The calculation of initial weight of Kanamycin
has to be done carefully in the case of different substances. Since
there was total concordance with a drug concentration of 5 mg/ml
and water as solvent and diluent no changes were made.
Ofloxacin: Four different solvents were used for Ofloxacin:
water, 0.1 m NaOH, DMSO, and propylene glycol. One
laboratory changed the drug concentration from 1 to 2 mg/ml
using BACTEC MGIT 960. Another reduced the drug concen-
trations tested from 2, 4, and 6 to only 2 mg/ml. PAS: The critical
drug concentration was reduced in two cases from 4 to 1 and 2,
and from 4 to 0.5 together with a change from using the BACTEC
460 to the Lo¨wenstein Jensen media. Another laboratory reduced
the drug concentrations tested from 2, 4, and 6 using the
BACTEC MGIT 960 to a single concentration of 4 mg/ml.
‘‘Baltic-Nordic TB-Laboratory Network’’: Phase II
Based on the good results of phase I, in the second panel the
proportion of resistant strains was increased considerably from a
mean of 13.6% to 41.4%. Best results were again achieved with
Ofloxacin testing (Table 1). Likewise an enhancement was
obtained for Capreomycin, Ethionamide/Protionamide and
PAS. For Amikacin and Cycloserine the results were poorer for
both susceptible and resistant strains.
The ‘‘WP3 of the TB PAN-NET’’ Project
In round 1, 13 laboratories agreed to participate in the
proficiency testing of a panel of 20 strains, which were laboratory
generated monoresistant strains (or polyresistant but sensitive to
first line drugs) to second line drugs (5 Fluoroquinolone resistant, 7
Kanamycin resistant, 6 Capreomycin resistant, from which 3 were
also Amikacin resistant and 3 borderline) (Figure 1). Susceptibility
of all 20 strains to FLD was confirmed by some laboratories.
Phenotypic and molecular testing of Fluoroquinolone resistance
showed 100% concordance between all laboratories (5 resistant
and 15 susceptible strains). Detection of resistance related
mutations of the injectable drugs Amikacin, Capreomycin, and
Kanamycin was also 100% concordant, whereas the phenotypic
testing showed unambiguous results only for Capreomycin (6
resistant and 14 susceptible) and Kanamycin (7 resistant and 13
susceptible). Regarding Amikacin, 3 strains (with no mutation in
the rrs gene) were identified as susceptible, mainly when using the
proportion method on solid medium, but resistant when mainly
using the MGIT liquid system. Two laboratories confirmed with
both methods the respective ‘‘susceptible’’ and ‘‘resistant’’ results.
One strain with the rrs mutation C1402T showed also
disconcordant results for Amikacin. In order to clarify how these
strains should be classified, the doubtful strains were retested and
underwent a MIC analysis. All strains showed elevated MIC levels
compared to the H37Rv reference strain, with the critical
concentration slightly lower (,40 mg/ml) when using the propor-
tion method on LJ medium and at the critical concentration
(1 mg/ml) with the MGIT method. We observed that the strains
showed elevated MIC levels dependant on the age of the
subculture. Since the laboratories agreed upon the fact that for
these 4 strains an unambiguous result could not be given, they
were classified as borderline but excluded from the quality control
panel. In order to generate a greater number of strains
monoresistant to SLD or polyresistant (but not MDR), a second
round of 20 strains were prepared ‘‘in vitro’’ and tested. Again, the
Fluoroquinolone testing revealed a high interlaboratory concor-
dance rate (99.5%, only 1 false resistant result). Kanamycin testing
of the panel also showed a high concordance rate (98.3%, only 2
false susceptible results). Capreomycin testing however was again
less concordant with 2 strains and Amikacin testing with 3 strains
showing ambiguous results; these were excluded from the quality
control panel. From both rounds of proficiency testing the
selection of robustly characterized strains for SLD DST was
finalized (Table 3).
‘‘ECDC ERLN-TB Network’’
All participating laboratories received an individual analysis
with a certificate (see example Figure 2). In the first round in
spring 2010 only FLD were tested showing high concordance rates
between the 31 participants (Table 4): Isoniazid (100%), Rifam-
picin (98.1%), Ethambutol (99.4%), Pyrazinamide (98.2%), and
Streptomycin (99.3%). In the second to fourth round in autumn
2010, 2011 and 2012, FLD and SLD were tested again with high
concordance rates between 23, 25, and 23 participants, respec-
tively (Table 4): Isoniazid (98.2%, 99.6%, and 100%), Rifampicin
(97.4%, 100%, and 99.1%), Ethambutol (96.5%, 97.4%, and
99.5%), Pyrazinamide (86.7%, 94.0%, and 97.6%), Streptomycin
Table 1. Agreement of SLD testing in different laboratories in phase I and phase II of the ‘‘Baltic-Nordic TB-Laboratory Network’’
study.
Concordance % (no. of strains)
Strains Amikacin Capreomycin Cycloserine
Ethionamide/
Protionamide Kanamycin Ofloxacin PAS
Phase I
susceptible 95.3 (17) 97.7 (16) 96.4 (20) 87.9 (14) 100 (16) 99.4 (19) 92.6 (19)
Resistent 84.7 (3) 71.0 (4) No strains 71.3 (6) 91.7 (4) 88.9 (1) 80.0 (1)
Total 93.8 (20) 92.3 (20) 96.4 (20) 82.9 (20) 98.3 (20) 98.9 (20) 92 (20)
Phase II
susceptible 86.7 (5) 100 (6) 91.8 (7) 89.1 (6) 93.3 (5) 100 (6) 97.5 (5)
resistent 60.0 (5) 88.9 (4) 66.7 (3) 81.9 (4) 96.7 (5) 95 (4) 91.8 (5)
Total 71.1 (10) 95.6 (10) 84.3 (10) 86.2 (10) 95.0 (10) 98.0 (10) 94.6 (10)
PAS, p-amino salicylic acid.
doi:10.1371/journal.pone.0076765.t001
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(95.5%, 98.3%, and 98.8%), Fluoroquinolones (100%, 100%, and
98.1%), Amikacin (100%, 96.1%, and 99.4%), and Capreomycin
(94.5%, 100%, and 98.2%).
Certificates were issued for all 31 participants in spring 2010, 21
of 23 (91.3%) in autumn 2010, 24 of 25 (96%) in autumn 2011,
and all 23 (100%) in autumn 2012. Despite the high summarized
concordance rates, deviations were found with false susceptible
results highest with Ethambutol (15.8%), Kanamycin (11.4%), and
Pyrazinamide (8.1%), and false resistant results highest with
Pyrazinamide (5.6%) (Table 4).
Altogether three different panels were analyzed with molecular
methods by between18 and 26 participants, using 5 crude DNA
extracts in autumn 2010, and 10 strains plus 6 additional DNAs in
autumn 2011 and 2012. The majority of laboratories used line
probe assays (95% in 2010, 100% in 2011, and 96% in 2012, with
only a few applying DNA sequencing alone or in combination,
and additionally one laboratory a PCR amplification-restriction
analysis). In comparison to phenotypic methods, the concordance
rates were even higher with 99.0% for Isoniazid (n = 88
participants in 4 rounds), 99.1% for Rifampicin (n = 87), 99.3%
for Ethambutol (n = 66), 100% for Pyrazinamide (n= 2), 88.9% for
Streptomycin (n = 2), 99.7% for Flouroquinolones (n = 64), and
99.6% for Amikacin and Capreomycin (n = 63). Rates of false
resistant results were correspondingly low ranging from 0.3%
(Amikacin, Capreomycin, Ethambutol) to 1.5% (Isoniazid), and
false susceptible results ranged from 1% (Isoniazid) to 1.5%
(Rifampicin). Calculation of false resistant and susceptible results
was excluded for antibiotics for which only a low number of
resistant strains were tested or few participants sent results.
Discussion
Laboratory services have an important role in improving the
delivery of health care and reducing the prevalence of TB,
particularly drug resistant TB. Quality control and proficiency
testing are fundamental tools that ensure accuracy in laboratories
by comparing quality to other laboratories, evaluating the general
performance level of the laboratory’s service, and detecting
laboratory facilities with unacceptable levels of proficiency. This
concept culminated in the establishment of the current suprana-
tional network of the WHO/IUATLD with their external quality
assurance system.
In the present multicenter study one aim was to establish a
network as the basis for high quality accurate SLD susceptibility
testing. Our second goal was to assess whether we, as a network,
could improve the reliability of DST results. Based on the
experience with FLD it is known that continued proficiency testing
with exchange of information and technical assistance has led to
improved DST quality of participating laboratories [16].We
observed a similar improvement in performance in SLD testing
by participant laboratories.
Table 2. Methods applied in the different laboratories in both phases of SLD proficiency testing (‘‘Baltic-Nordic TB-Laboratory
Network’’ study).
Drug concentration in mg/ml (number of laboratories*)
Drug Proportion method Critical concentration BACTEC MGIT MIC
Amikacin 20+40 (2) 6 (1), 8 (1) 1(6) 1(3)
Capreomycin 20+40 (2) 2 (1) 1.25 (5), 5 (1) 2.5 (3)
Cycloserine 30 (5); 20+40 (1) 40 (1) 30, 40 (1)
Ethionamide/
Protionamide
20+40 (1); 2.5 (3), 5 (2) 2.5 (3) 4 (1)
Kanamycin 20+40 (2) 5 (3) 5 (3)
Ofloxacin 0.5+1+2 (1) 2.5 (1) 2(6) 1 (1), 2 (2) 4 (1)
PAS 0.25 (1); 0.5 (2); 0.5+1(1) 1+2(1); 2(1); 4(1) 4 (1) 2 (1)
*some laboratories used more than one method.
PAS, p-amino salicylic acid.
LJ, Lo¨wenstein Jensen; MIC, minimal inhibitory concentration.
doi:10.1371/journal.pone.0076765.t002
Figure 1. Compilation of strains in round 1 of the WP3 of the TB PAN-NET’’ project.
doi:10.1371/journal.pone.0076765.g001
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The highest improvements were found in the Baltic-Nordic
TB-Laboratory Network study from round I to round II
resulting in a rise in the concordance rates in the category of
resistant strains for Ofloxacin (from 88.9 to 95.0%), Kanamycin
(from 91.7 to 96.7%), and Capreomycin (from 71.0 to 88.9%)
testing. Within the other networks the improvement was smaller
but started from a higher base-line of accuracy.
One of the major outcomes from these studies was the finding
that the reliability of phenotypical SLD depends on the drug
tested. As already well known for FLD differences in DST depend
on the drug compound used. Isoniazid and Rifampicin resistance
can be reliably measured; resistance to Pyrazinamide, Ethambutol,
and Streptomycin is more difficult [11,17–19]. Long-term studies
undertaken in 1994–2002 revealed average sensitivities to detect
resistance to Isoniazid of 98.7% and to Rifampicin 97.2% [20].
Although in our studies the number of samples is not comparable
to the many rounds of proficiency testing of FLD over a long time
period, we could show that for Ofloxacin, Kanamycin and
Capreomycin a concordance of .95% could be achieved. In Italy
also a pilot round of SLD in 2010 showed similar results with
.95% specificity and efficiency [21]. The analysis of 57733 tests of
DST for FLD in the U.S from 1994 to 2008 yielded a significantly
higher agreement of susceptible strains (98.4%) compared to
resistant strains (91%) [22]. This can also be seen by comparison of
phase I and II in the Baltic-Nordic TB-Laboratory Network
study (Table 1) with decreased concordance rates in the second
phase, where the proportion of resistant strains was higher. There
was general agreement among participants for biosafety reasons to
avoid sending highly drug resistant strains for quality control
purposes around the world. Consequently, we developed a selected
panel of in vitro generated resistant strains with single or poly drug
resistance to FLD and SLD but without MDRTB. This panel was
tested, characterized and a selection of reliable strains was made.
There was a discussion as to whether the more problematic strains
should be used, since a laboratory has to deal with borderline
results as well. In our opinion only unambiguous strains
(susceptible or resistant) should be used, since the overall
Table 3. Agreement of SLD results between laboratories in the ‘‘Workpackage 3 of the FP7 TB PAN-NET’’.
Concordance % (no. of strains tested, no of tests performed*)
Molecular methods** Phenotypic methods***
Drug tested Susceptible strains Resistent strains Susceptible strains Resistent strains
Ofloxacin 100% (40, 490) 100% (15, 185) 99.8% (40, 490) 100% (185)
Amikacin 100% (47, 577) 100% (9, 111) 99.8% (39, 469) 100% (9, 111)
Capreomycin 100% (44, 540) 100% (12, 148) 98.5% (37, 327) 95.2% (17, 209)
Kanamycin 100% (44, 540) 100% (12, 148) 98.7% (38, 458) 96.7% (18, 139)
*All strains were tested in three rounds of testing: round 1 (n = 13), in the intermediate round (n = 11), and in round 2 of the ‘‘Workpackage 3 of the FP7 TB PAN-NET’’.
**All laboratories applied line probe assays, some additionally DNA sequencing methods.
***The majority of laboratories applied MGIT 960 DST, some the proportion method on solid media, but the data are incomplete; intermediate level strains were
excluded from this analysis.
doi:10.1371/journal.pone.0076765.t003
Figure 2. Certificates issued for a succesful EQA round.
doi:10.1371/journal.pone.0076765.g002
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improvement of quality was the main goal, which can be done
most easily with clear defined strains.
We are convinced that second line DST results can be
considered as reliable and comparable to some FLD. Furthermore
we now have the capacity to reliably identify XDR strains
(multidrug resistant strains with additional resistance to a
Fluoroquinolone and an injectable drug).
Noteworthy was the high concordance of results with molecular
methods, although these samples were tested for the first time. The
reason for this may be that the molecular methods are less
dependent on personal handling than conventional DST. Sources
of errors, such as sample mix up or technical errors may occur
with both molecular and microbiological methods, but factors like
the critical inoculum size for example require experienced
technicians to reduce variability for microbiological DST methods.
The long-term objective of the projects was to set up a
functioning network to improve and control the quality of DST for
SLDs in all participating countries. The main factor for
influencing the success of this network was the exchange of
information between the project partners to rule out major
technical problems such as usage of the proper solvent and
concentration of the drugs to be tested.
The networks included laboratories from more than 30
countries. It can serve as a model system for other unconnected
countries and all laboratories which want to participate in a system
that has proven to be efficient in proficiency testing.
Until now INSTAND offers only testing for microscopy,
primary culture, culture differentiation, Nucleic Acid Amplifica-
tion Tests (NAAT), and FLD, but this may be expanded with SLD
and the detection of resistance related mutations by molecular
methods. If the decision is made to include new methods for
quality control, the newly developed laboratory-generated strains
may serve as a basis of strains having the advantages of being well
characterized, no mixed populations, and safe due to single drug
resistances.
With the multicenter studies presented here, we have shown
that it is possible to produce reliable results for many SLDs
between laboratories applying different analytical methods. The
application of molecular methods also yielded a high degree of
interlaboratory concordance. The joint correction and adjustment
of techniques yielded an improvement of quality in laboratories in
many countries.
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Isoniazid 100 (124) 100 (31) 97.8 (90) 100 (23) 99.4 (174) 100 (75) 100 (184) 100 (46) 99.5 (572) 100 (175)
Rifampicin 98.9 (93) 96.8 (93) 97.8 (92) 95.5 (93) 100 (174) 100 (75) 99.5 (207) 95.5 (22) 99.3 (566) 97.8 (181)
Ethambutol 99.4 (154) n.d. 96.5 (114) n.d. 98.6 (216) 84.2 (19) 99.5 (207) n.d. 98.7 (691) 84.2 (19)
Pyrazinamide 97.7 (88) 100 (22) 86.7 (75) n.d. 94.4 (197) 90 (20) 98.9 (188) 85.0 (20) 95.4 (548) 91.9 (62)
Streptomycin 99.2 (119) 100 (30) 97.1 (69) 90 (20) 99.5 (190) 93.8 (48) 98.6 (220) 99.2 (119) 98.8 (598) 97.2 (217)
Ofloxacin n.d.*** n.d. 100 (65) n.d. 100 (161) 100 (17) 98.6 (144) 94.1 (17) 99.5 (370) 97.1 (34)
Amikacin n.d. n.d. 100 (53) n.d. 96.1 (179) n.d. 100 (136) 97.1 (34) 98.1 (368) 97.1 (34)
Capreomycin n.d. n.d. 96.4 (55) n.d. 100 (158) n.d. 100 (136) 91.2 (34) 99.4 (349) 91.2 (34)
Kanamycin n.d. n.d. n.d. n.d. 100 (116) 76.9 (13) 100 (96) 95.5 (22) 100 (212) 88.6 (35)
*The majority of laboratories applied MGIT 960 DST, only one laboratory performed the proportion method on solid media, but the data are incomplete.
**susc. = susceptible, res. = resistant; intermediate level strains were excluded from this analysis.
***n.d. = not done.
doi:10.1371/journal.pone.0076765.t004
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